Sana stock soars on diabetes therapy data, UniQure's offering, BioInvent's lymphoma success, Alpha's Zunveyl deal, Neumirna funding, and Cassava's layoffs.
A new startup aiming to tackle rare diseases de-stealthed Wednesday morning with a CEO experienced in the space. Alesta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback